Mesnex 400 mg/4 ml (IV Injection)

Indications

• prophylactic agent
• preventing ifosfamide-induced hemorrhagic cystitis
• preventing high dose cyclophosphamide-induced hemorrhagic cystitis

Pharmacology

• rapidly oxidized to major metabolite Mesna disulfide (diMesna)
• detoxifies urotoxic ifosfamide metabolites
• reduces risk of hemorrhagic cystitis
• does not interfere with antitumor efficacy

Dosage & Administration

• fractionated dosing schedule
• intravenous bolus injections
• total daily dose is 60% of ifosfamide dose
• preparation of Intravenous Solutions/Stability

Interaction

• no clinical drug interaction studies conducted

Contraindications

• known hypersensitivity to Mesna or excipients

Side Effects

• colic
• depression
• diarrhea
• fatigue
• headache
• hypotension
• irritability
• joint pains
• nausea
• rash
• tachycardia
• vomiting

Pregnancy & Lactation

• Pregancy Category B
• no adequate and well-controlled studies in pregnant women
• not known whether drug is excreted in human milk
• decision whether to discontinue nursing or drug

Precautions & Warnings

• allergic reactions reported
• higher incidence in patients with autoimmune disorders
• Mesnex does not prevent or alleviate other adverse reactions
• up to 6% of patients developed hematuria
• dosage reductions or discontinuation of therapy for severe hematuria
• not effective in reducing risk of hematuria due to other pathological conditions
• benzyl alcohol content caution in pediatric patients

Overdose Effects

• no known antidote
• lethal to mice and rats at high doses

Therapeutic Class

• antidote preparations

Storage Conditions

• store in the original carton at 20°C-25°C
• protect from light
• keep out of the reach of children

Related Brands